Synopsis: Shares of Eris Lifesciences Limited fell nearly 6 percent on April 21, 2026 after the Croatian Agency for Medicinal Products and Medical Devices issued non-compliance observations for the company’s Swiss Parenterals Unit 1 and Unit 2 facilities following an inspection conducted between March 9 and March 13.
Shares of a Hyderabad-based specialty pharmaceutical company came under sharp selling pressure on April 21, 2026 after the Croatian Agency for Medicinal Products and Medical Devices known by its Croatian acronym HALMED disclosed non-compliance observations following an audit of the company’s Swiss Parenterals Unit 1 and Unit 2 manufacturing facilities. The inspection was conducted between March 9 and March 13, 2026. The stock hit an intraday low of Rs. 1,352 per share during Tuesday’s session, representing a decline of close to 6 percent from the prior close.
With a market capitalisation of approximately Rs. 20,049 crore, the shares of Eris Lifesciences Limited were last quoted at Rs. 1,400 on BSE as of midday trading on April 21, 2026 as per available data.
The stock has gained approximately 6.6 percent over the past month but remains roughly 9.8 percent in the red for the calendar year. The 52-week range is Rs. 1,097 to Rs. 1,910, with the stock trading at a P/E of approximately 43 times apiece.
HALMED is Croatia’s national medicines regulator and a member agency of the European Medicines Agency’s network meaning its Good Manufacturing Practice inspections are conducted under EU GMP standards and carry regulatory standing within the European Economic Area.
A non-compliance observation from HALMED does not automatically translate into a product recall, export ban, or facility shutdown, but it does trigger a formal remediation process that requires documented corrective and preventive action, and in more serious cases can affect the facility’s EU GMP certificate status.
The Swiss Parenterals facilities are not peripheral to Eris Lifesciences, they are central to it. Eris acquired Swiss Parenterals Pvt. Ltd., a Vapi-based injectable pharmaceutical manufacturer, in 2022 for approximately Rs. 500 crore, marking its entry into the high-growth institutional and critical care injectables space. Unit 1 and Unit 2 cover sterile injectable manufacturing including vials, ampoules, and lyophilised products, the formats required for hospital formularies, oncology, nephrology, and critical care, all segments Eris has been aggressively building through both acquisitions and organic portfolio expansion.
Business Overview
Incorporated in 2007, Eris Lifesciences Limited manufactures, markets, and distributes domestic branded formulations focused on chronic and sub-chronic therapies including anti-diabetes, cardiovascular, dermatology, neuropsychiatry, oncology, and nephrology. It operates through divisions including Eris, Nikkos, Adura, Montana, and Eris Kinedex, with Swiss Parenterals anchoring
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
